TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05999058

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dacryoendoscopic-assisted laser dacryoplasty with silicone intubation
Description: The dacryoendoscopy was inserted into the lacrimal duct through the upper or lower lacrimal punctum. When the dacryoendoscopy reached the postsaccal obstruction, laser dacryoplasty (FOX diode laser, A.R.C. Laser, Nürnberg, Germany) was performed by widening the stenotic or obstructed section. After removing the dacryoendoscopy, a silicone tube inserted into lacrimal passage. Double bicanalicular silicone intubation was performed as previously described.
Study: NCT02343627

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle of test product
Description: Vehicle of test product applied to infected toe nails and 0.5 mm of adjacent skin once daily for 60 days.
Study: NCT03403660

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: non White coat
Description: Postpartum patients are randomized to either arm of the study (white coat or standard scrub suit only) by location. All the obstetric physicians associated with patient's postpartum care should use or not use white coat in every single encounter with patient.
Study: NCT00202436

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Phlebotomy
Description: Removal of 500 ml whole blood

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Phlebotomy
Description: Removal of 500 ml whole blood

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erythrocytapheresis
Description: machinal removal of erythrocytes

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erythrocytapheresis
Description: machinal removal of erythrocytes
Study: NCT04095884

Intervention type: PROCEDURE
Intervention: blood sampling
Description: observational study and no intervention will be given. only blood samples collected and treated with iron supplements

Intervention type: PROCEDURE
Intervention: blood sampling
Description: observational study and no intervention will be given. only blood samples collected and treated with iron supplements

Intervention type: PROCEDURE
Intervention: blood sampling
Description: observational study and no intervention will be given. only blood samples collected and treated with iron supplements

Intervention type: PROCEDURE
Intervention: blood sampling
Description: observational study and no intervention will be given. only blood samples collected and treated with iron supplements
Study: NCT00862706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telbivudine/LDT600A
Description: Oral once daily
Study: NCT03155113

Intervention type: OTHER
Group type: OTHER
Intervention: blood drawing
Description: Before starting therapy a blood sample will be collected from any subject.
Study: NCT05397262

Intervention type: OTHER
Group type: OTHER
Intervention: Hyperthermia
Description: Deep Regional Hyperthermia (RHT) 1-2/week up to 10 sessions a type of cancer treatment in which body tissue is exposed to high temperatures (up to 113°F).

Intervention type: RADIATION
Group type: OTHER
Intervention: Radiotherapy
Description: 50,4 Gy (28 x 1,8 Gy) plus Boost: If R0: 5,4 Gy; If R1/2: 9 Gy

Intervention type: DRUG
Group type: OTHER
Intervention: Chemotherapy 5-Fluorouracil
Description: 600 mg/m\^2 civ 120h; d 1-5, 29-33

Intervention type: DRUG
Group type: OTHER
Intervention: Chemotherapy Cisplatin
Description: 20 mg/m\^2; d1-5, 29-33
Study: NCT02259049

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: L-tyrosine
Description: Each subject will receive 2,000 mg of L-tyrosine BID for 24 hours.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: L-tyrosine
Description: Each subject will receive 2,000 mg of L-tyrosine BID for 24 hours.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sugar Pill
Description: Each subject will receive a sugar pill BID for 24 hours.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Description: Each subject will receive a sugar pill BID for 24 hours.
Study: NCT03901989

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: zeolite
Description: given for a period of 12 months

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: cellulose
Description: given for a period of 12 months
Study: NCT01354444

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol
Description: target dose of 25 mg daily which is half the maximum dose used in clinical practice

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: a pill that will look like the active drug but will not contain any carvedilol
Study: NCT02854241

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biannual ultrasonography
Description: Biannual ultrasonography for HCC surveillance, performed by board-certified radiologists.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Annual noncontrast liver MRI
Description: Annual noncontrast liver MRI consisted of T2WI, precontrast T1WI, dual-echo image, DWI (single shot, multishot) and T2 map.~DWI using multishot and T2 map are not included for initial MR reading.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Contrast enhanced liver CT
Description: In patients without report of HCC during surveillance period, contrast CT is performed 6 months after the last MR scan.
Study: NCT03035084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Single oral dose of 50,000 IU of vitamin D3
Study: NCT00735306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin
Description: Avastin 10 mg/kg IV on days 1, 15 and 29 Begins the first day of radiation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tarceva
Description: Daily by mouth per assigned dose, for 5.5 weeks Begins the first day of radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiation to the pancreas Monday through Friday for 28 treatments
Study: NCT02784873

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity interval training
Description: High intensity interval training within a standard cardiac rehabilitation programme
Study: NCT03902730

Intervention type: OTHER
Group type: OTHER
Intervention: Traditional Back Squat
Description: Participants will complete traditional back squat in this four treatment crossover design.

Intervention type: OTHER
Group type: OTHER
Intervention: Barefoot Back Squat
Description: Participants will complete barefoot back squat in this four treatment crossover design.
Study: NCT03612674

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard colonoscopy
Description: Current standard of care colonoscopy.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ARC Endocuff Vision
Description: Subjects randomized to undergo a colonoscopy procedure with ARC Endocuff Vision will have this device placed on the top of the colonoscope used during their procedure.
Study: NCT01807494

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total hip replacement components
Description: All patients will receive the same implants
Study: NCT03902730

Intervention type: OTHER
Group type: OTHER
Intervention: Box Squat
Description: Participants will complete box squat in this four treatment crossover design.

Intervention type: OTHER
Group type: OTHER
Intervention: Traditional Back Squat with Chains
Description: Participants will complete traditional back squat with chains in this four treatment crossover design.
Study: NCT03219554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: oral palbociclib 125mg daily for 21days followed by a 7-day break. Cycle will be repeated every 28 days.
Study: NCT04229173

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MRI acquisition
Description: MRI acquisition

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MRI acquisition
Description: MRI acquisition

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: DAT-SPECT
Description: Imaging with DAT SPECT (Dopamine Transporter, Single Photon Emission Computed Tomography)
Study: NCT03035084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D2
Description: Single oral dose of 50,000 IU of vitamin D2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D2
Description: Single oral dose of 50,000 IU of vitamin D2

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D2
Description: Single oral dose of 50,000 IU of vitamin D2

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo oral capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo oral capsule
Study: NCT03903614

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SML
Description: SML consists of supervised handwriting practice, fitness exercises, and fine motor speed drills that preferentially belabor a participant's right eye, ear, hand and leg during therapy.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CON
Description: CON consists of supervised handwriting practice, fitness exercises, and fine motor speed drills on the participant's dominant hand.
Study: NCT02672891

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: condom balloon catheter
Description: The condom balloon catheters were inserted into the uterine cavity digitally or with forceps .Tight vaginal pack was inserted or cervical stitch was done to prevent displacement of the balloon catheter.~(2)-Insertion at Cesarean Section: The catheter was inserted through the uterine incision (pushing the tip to the fundus and the drainage port through the cervix into the vagina) or transvaginally and inﬂated after the uterine incision was closed.
Study: NCT00143130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Pregabalin
Study: NCT04593238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Double Antibiotic paste
Description: Metronidazole and Ciprofloxacin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Hydroxide Paste - Non-Setting
Description: Calcium hydroxide paste to be delivered inside the canal as an intra-canal medication
Study: NCT05967858

Intervention type: OTHER
Intervention: observation
Description: no intervention

Intervention type: OTHER
Intervention: observation
Description: no intervention
Study: NCT00461019

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implantation and activation of the vagus nerve stimulator
Description: Implantation of the nerve stimulator, cuff nerve electrode and RV sensing lead
Study: NCT01605448

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction (MBSR)
Description: 8 weekly classes of meditation/yoga
Study: NCT03486574

Intervention type: DIAGNOSTIC_TEST
Intervention: Positive result from pathological test
Description: Presence/absence of gastric cancer will be evaluated by upper gastroendoscopy or results of pathological test
Study: NCT01296815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Intralesional bevacizumab, dosis of 5mg/cm2, injections every 2 weeks, total number of injections: 3
Study: NCT03574103

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Caloric restriction only
Description: Participants in this group will receive a eating plan with caloric restriction (513 to 770 kcal from estimated energy requirements), without restriction in time for feeding, for 8 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caloric restriction plus TRF morning
Description: Participants in this group will receive a eating plan with caloric restriction (513 to 770 kcal from estimated energy requirements) and 8 hours for eating (from 12 p.m. to 8 p.m.) and 16 hours of fasting, for 8 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caloric restriction plus TRF night
Description: Participants in this group will receive a eating plan with caloric restriction (513 to 770 kcal from estimated energy requirements) and 8 hours for eating (from 8 a.m. to 4 p.m.) and 16 hours of fasting, for 8 weeks.
Study: NCT00909961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Study: NCT01149759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine A
Description: 5 mg/kg for first 4 weeks, followed by tapering to 1 mg/kg for 12 weeks until discontinuation at 16 weeks
Study: NCT02132559

Intervention type: DRUG
Intervention: DHEA
Study: NCT00201149

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient-centered Counseling
Description: To improve patients' adherence with prescribed anti-hypertensive medication, improve blood pressure control and doctor-patient communication, we propose a three-armed randomized controlled trial in the internal medicine clinics of a large metropolitan teaching hospital which serves a large percentage of poor African American and white patients. We will implement an intervention strategy by teaching clinicians to counsel patients about hypertension control through the use of patient-centered counseling and by providing office-based support; critical to facilitating clinicians' use of this strategy. Through this intervention we will provide clinicians with communication skills that are proven to help patients change risk-related behaviors, and which will enhance doctor-patient communication.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient-centered Counseling
Description: To improve patients' adherence with prescribed anti-hypertensive medication, improve blood pressure control and doctor-patient communication, we propose a three-armed randomized controlled trial in the internal medicine clinics of a large metropolitan teaching hospital which serves a large percentage of poor African American and white patients. We will implement an intervention strategy by teaching clinicians to counsel patients about hypertension control through the use of patient-centered counseling and by providing office-based support; critical to facilitating clinicians' use of this strategy. Through this intervention we will provide clinicians with communication skills that are proven to help patients change risk-related behaviors, and which will enhance doctor-patient communication.
Study: NCT00936182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Description: Fluconazole daily for 30 days
Study: NCT04229173

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: blood sample, cerebrospinal fluid (optional)
Description: blood sample, cerebrospinal fluid

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Evaluations about motor abilities, depression, cognition and lifestyle
Description: Evaluations about motor abilities (UMSAR scale), depression (BDI scale), cognition (MoCA scale) and lifestyle (MSA- QoL)

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Evaluation about depression cognition
Description: Evaluations about depression (BDI scale), cognition (MoCA scale)
Study: NCT00642278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin (JNJ-28431754)
Description: One 50 mg, 100 mg, 200 mg, or 300 mg over-encapsulated tablet orally (by mouth) once daily for 12 weeks or one 300 mg over-encapsulated tablet orally twice daily for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin (JNJ-28431754)
Description: One 50 mg, 100 mg, 200 mg, or 300 mg over-encapsulated tablet orally (by mouth) once daily for 12 weeks or one 300 mg over-encapsulated tablet orally twice daily for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin (JNJ-28431754)
Description: One 50 mg, 100 mg, 200 mg, or 300 mg over-encapsulated tablet orally (by mouth) once daily for 12 weeks or one 300 mg over-encapsulated tablet orally twice daily for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin (JNJ-28431754)
Description: One 50 mg, 100 mg, 200 mg, or 300 mg over-encapsulated tablet orally (by mouth) once daily for 12 weeks or one 300 mg over-encapsulated tablet orally twice daily for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin (JNJ-28431754)
Description: One 50 mg, 100 mg, 200 mg, or 300 mg over-encapsulated tablet orally (by mouth) once daily for 12 weeks or one 300 mg over-encapsulated tablet orally twice daily for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: One 100 mg over-encapsulated tablet orally (by mouth) once daily for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One matching placebo capsule orally (by mouth) once or twice daily for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One matching placebo capsule orally (by mouth) once or twice daily for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One matching placebo capsule orally (by mouth) once or twice daily for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One matching placebo capsule orally (by mouth) once or twice daily for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One matching placebo capsule orally (by mouth) once or twice daily for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: One matching placebo capsule orally (by mouth) once or twice daily for 12 weeks.
Study: NCT03661697

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser Therapy
Description: Clear and Brilliant Permea is a 1927nm fractional laser with 3 settings; low, medium, high.~All interventions were done at low with four passes to each participant's full face.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser Therapy
Description: Clear and Brilliant Permea is a 1927nm fractional laser with 3 settings; low, medium, high.~All interventions were done at low with four passes to each participant's full face.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Basic Skin Care Regimen
Description: Skin Medica brand cleanser, sunscreen, moisturizer as directed for 12 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Basic Skin Care Regimen
Description: Skin Medica brand cleanser, sunscreen, moisturizer as directed for 12 weeks
Study: NCT00936182

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluconazole
Description: Fluconazole daily for 30 days
Study: NCT03661697

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lytera
Description: cosmeceutical serum applied to face daily for 12 weeks
Study: NCT01025453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus and Sorafenib
Description: Treatment will be with sorafenib 200 mg orally twice a day and temsirolimus 25 mg intravenous weekly. A cycle will be equivalent to 4 weeks of treatment.
Study: NCT00792935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0941
Description: MK-0941 will be taken three times a day (TID), within 15 minutes before each meal. MK-0941 will be titrated to a maximally effective dose. The treatment period will be 6 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: Glimepiride will be taken once a day (QD) in the morning, within 15 minutes before the breakfast meal. Glimepiride will be titrated to a maximally effective dose. The treatment period is 6 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: The study will include an up to 4-week metformin dose titration/dose stabilization period. Once a participant has reached the maximum tolerated dose of metformin \[(i.e., ≥1500 mg/day and ≤2550 mg/day (or ≤3000 mg/day, where the maximum dose of metformin per the local label is 3000 mg/day)\], the participant should remain on the same metformin dose throughout the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: The study will include an up to 4-week metformin dose titration/dose stabilization period. Once a participant has reached the maximum tolerated dose of metformin \[(i.e., ≥1500 mg/day and ≤2550 mg/day (or ≤3000 mg/day, where the maximum dose of metformin per the local label is 3000 mg/day)\], the participant should remain on the same metformin dose throughout the study.
Study: NCT01059344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesalamin
Description: 4.8g/day, 800 mg tablets
Study: NCT02771574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lyo avexitide
Description: Lyophilized avexitide (Lyo avexitide) administered subcutaneously (sc)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lyo avexitide
Description: Lyophilized avexitide (Lyo avexitide) administered subcutaneously (sc)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lyo avexitide
Description: Lyophilized avexitide (Lyo avexitide) administered subcutaneously (sc)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lyo avexitide
Description: Lyophilized avexitide (Lyo avexitide) administered subcutaneously (sc)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liq avexitide
Description: Liquid avexitide (Liq avexitide) administered subcutaneously (sc)
Study: NCT02382874

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intravenous injection
Description: Intravenous injection of AD-MSC to the patients with FSGS
Study: NCT01133756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: lenvatinib (as 1mg, 4mg, and 10mg tablets) was administered orally, once daily continuously for each 21-day treatment cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin was to be administered on Day 1 of every 21-day cycle at a dose AUC 4 over 30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin was to be administered on Day 1 of every 21-day cycle at a dose AUC 4 over 30 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine was to be administered on Day 1 and Day 8 of every 21-day cycle at a dose of 1000 mg/m2 over 30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine was to be administered on Day 1 and Day 8 of every 21-day cycle at a dose of 1000 mg/m2 over 30 minutes.
Study: NCT03620292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab-IRDye800CW
Description: Intravenous administration of Bevacizumab-IRDye800CW prior to surgery for hilar cholangiocarcinoma

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: near infrared (NIR) fluorescence imaging
Description: Intraoperative NIR fluorescence imaging of hilar cholangiocarcinoma, lymph nodes, resection margins, resection specimens